Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally

The chief medical officer of Stoke Therapeutics disposed of 14,311 Common Stock shares for a transaction value of $457,000 across three days ending March 19, 2026. This sale represented 26.01% of Ticho's direct common stockholdings before the transaction, reducing direct ownership from 55,013 to 40,702 shares.